India Today reports the Serum Institute of India (SII) CEO, Adar Poonawalla, as saying that India has barred the vaccine maker from exporting the Oxford University-AstraZeneca coronavirus vaccine for several months...
Reuters reports that “…an advantage of mRNA vaccine technology is that scientists can quickly re-engineer genetic material in the shot to match that of the mutated protein, whereas modifying traditional vaccines would require...
English
Japanese
